




Immunodex Announces Verifiable Immunity Passports to Reboot the Economy during COVID-19

Hong Kong SAR, China, 22 April, 2020 - Immunodex is proud to announce the launch of its Verifiable Immunity Passport (VIP), a digital proof-of-health that will allow immune individuals to return to everyday life.


Immunodex, a medical technology company, believes its Verifiable Immunity Passport (VIP) will ease quarantine and isolation restrictions by proving the health status of any individual tested for COVID-19. Immune individuals can be authorized the freedom of work, travel or other forms of mobility, while governments, healthcare systems and businesses can resume operations safely. This will put society on the path to economic recovery until a vaccine is available.



(Immunodex's Verifiable Immunity Passport is a blockchain-based registry that proves an individual's health status with regards to COVID-19 in a secure, tamper-proof and privacy-preserving way.)

Developed in collaboration with an international team of healthcare professionals and cryptography researchers, the VIP is a collection of certificates issued by an attesting party (such as a health authority or health care professional) that

verifies the holder of the VIP has fulfilled conditions of attaining a level of immunity to a disease (via diagnostic assessment or vaccination if available). Immunodex's VIP conforms with the World Wide Web Consortium (W3C) Verifiable Credentials guidelines, which outlines a recent technology that requires blockchain and privacy-preserving cryptography to make digital identities auditable, fraud-proof and therefore trustworthy to any verifying party.



(A brief schematic of how Immunodex's Verifiable Immunity Passport works)

Based on several years of proven proprietary cryptographic research, Immunodex's VIP is built to be provably secure and privacy-preserving. All data registered onto the certificates is owned by the holder (patient) and only revealed to other

verifying parties upon consent. Immunodex may further enhance privacy of all parties with integrated zero-knowledge proof cryptography and anonymous credential techniques. Their verifiable credentials technology is EU GDPR compliant.

The VIP's digital certificates are designed to be issued by authorized healthcare institutions who would administer and generate results of RT-PCR and antibody tests, the clinical diagnostic tools currently available. The VIP also has an option to generate cryptographic declarations based on at-home tests that biomedical manufacturers are planning to release. Additionally, Immunodex offers health authorities the ability to coordinate mass screening programmes — patients can schedule testing at a designated site and will be automatically updated with the results in their VIP. Immunodex's technology is capable of anonymizing collected epidemiological datasets to support government policies for controlling the pandemic, while simultaneously preparing for future public health threats.

The VIP is available for individuals as a secure mobile app with an intuitive, user-friendly interface. Upon the holder's consent, the relevant information is exchanged via scanning of a QR code. For healthcare providers, Immunodex's "plug-and-play" solution can be readily integrated into most clinical settings and government agencies, including with cross-border policies.

Digital immunity certificates have received support by prominent technology figures, such as Bill Gates during an "Ask-Me-Anything" session on Reddit last month. The US, UK and German governments have been reported to be working on some form of immunity credential to allow recovered, antibodies-positive people, estimated to be anywhere from 2.8% to 14% of the population, to return to the workforce.

Immunodex was founded by a multinational doctor-led team of experts in medicine, blockchain cryptography and health technology. It has been working with partners globally to deliver the next generation of user-centric verifiable credentials for immunizations, including vaccinations.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements that involve risks and uncertainties concerning our business, products, and financial results. Actual results may differ materially from the results predicted. More information about potential risk factors that could affect our business, products, and financial results are included in our annual report and reports subsequently filed by us with the Securities and Exchange Commission ("SEC"). All documents are available through the SEC's Electronic

Data Gathering Analysis and Retrieval System (EDGAR) at <http://www.sec.gov/> or from our website. Quantum Materials Corp. hereby disclaims any obligation to update the information provided above, including forward-looking statements publicly, to reflect subsequent events or circumstances.

IMMUNODEX CONTACTS:

Dr. Anna Der, MD
Chief Medical Officer
dr.der@immunodex.com